Clinical Trial Update: ISIS 3521 in Treating Patients With Advanced, Unresectable, or Metastatic Non-small Cell Lung Cancer or Unresectable or Metastatic Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial update for ISIS 3521 in patients with advanced, unresectable, or metastatic non-small cell lung cancer or unresectable/metastatic melanoma; the st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Non-small Cell Lung Cancer

Drugs mentioned

• ISIS 3521 (LY900003)

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: Lung Cancer, Melanoma (Skin) | Phase 2 | Status: COMPLETED